increases exponentially when the international normalized ratio (INR) rises to 4.5-5.0 (Hylek et al., 2001; Pineo & Hull, 2003) .
Patients with cancer tend to experience greater difficulty maintaining INRs in the therapeutic value range, with INRs exceeding 4.5 for longer durations (Bona, Sivjee, Hickey, Wallace, & Wajcs, 1995; Hylek et al., 2001 ). This may result from the disease process, cancer medications, or the hypercoagulable state of many patients. Thus, the administration of anticoagulants to patients with cancer often requires frequent monitoring and dose modifications. Anticoagulant use has disadvantages, including adverse events, demands on patients' and clinicians' time, the number of interventions required, and costs to the healthcare system. A low-dose anticoagulant would be desirable if it did not require frequent monitoring and proved efficacious (Coccheri, Palareti, & Cosmi, 1999) .
Research on low-dose anticoagulant therapy was conducted first on surgical patients (De Takats, 1950) . By the late 1980s, researchers had concluded that warfarin caused no changes in prothrombin time or the levels of clotting factors II, VII, IX, and X (Bern et al., 1990 Data Synthesis: Meta-analysis of four studies (N = 1,236 patients) revealed that 6.4% of warfarin-treated patients experienced a thrombotic event compared with 7.5% in the control (no treatment) group. The risk difference for thrombus formation was not significant (2.0%, confidence interval = -9.0% to 5.0%).
Conclusions: The administration of warfarin did not reduce the incidence of symptomatic or asymptomatic CVC-associated thrombosis in patients with cancer.
Implications for Nursing: Using research findings to inform clinical nursing practice is important in caring for patients and providing optimal and improved patient outcomes. Prophylactic use of low-dose warfarin may not prevent thrombus formation and is associated with potentially adverse patient outcomes. Edmonton, Canada; and Christine V. Newburn-Cook, RN, PhD, is ➤ Central venous catheter-related thrombosis is a common complication and a significant cause of morbidity and mortality in patients with cancer.
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➤ The routine use of low-dose warfarin as prophylaxis does not significantly reduce the incidence of thrombus formation and is associated with potentially adverse patient outcomes.
